Diabetic Retinopathy Market Overview 2030:
The global diabetic retinopathy market size was valued at $3,086.00 million in 2020, and is projected to reach $10,785.50 million by 2030, registering a CAGR of 13.7% from 2021 to 2030. Diabetic retinopathy (DR) is an eye disease associated with diabetic patients. The disease occurs when there is damage to the retina due to diabetes. Without timely treatment, the disease may lead to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is among the common cause of loss of vision in the diabetic population; eventually leading to blindness.
At first, diabetic retinopathy might cause no symptoms or only mild vision problems. However, it can lead to blindness. The condition can develop in anyone who has type 1 or type 2 diabetes. The longer a person has diabetes with less controlled blood sugar can lead to eye complication. Diabetic retinopathy can lead to other serious eye conditions such as diabetic macular edema, retinal detachment, and neovascular glaucoma.
Increase in prevalence of diabetes, rise in geriatric population, growth in incidence of blindness due to diabetes, and augment of focus on awareness that facilitates early diagnosis to control the diseases drive the market. However, this growth is limited by dearth of skilled ophthalmologists, and extended approval time for drugs. Conversely, emergence of combined therapies for treatment of diabetic macular edema and the emerging markets of the Asia-Pacific and LAMEA regions are expected to provide several opportunities for diabetic retinopathy market growth during the forecast period.
Impact Of Covid-19 On Diabetic Retinopathy Market (Pre And Post Analysis)
The outbreak of COVID-19 has disrupted workflows in the healthcare sector globally. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. The overall impact of the COVID-19 pandemic was negative for key players in the Diabetic Retinopathy market. The COVID-19 pandemic led to disruptions in the healthcare facilities. Ophthalmic outpatient visits were broadly reduced to urgent and emergent cases only, and the procedures along with operations were postponed. There has been a decline of 81% in the ophthalmology clinic visits in March and April 2020 compared to the same period in 2019 as the patients avoided hospital visits. Retina clinics experienced about a 71% volume loss. Unlike other specialties, the transition to tele-ophthalmology visits was limited, as ophthalmological care is heavily dependent on specialized imaging equipment that is not readily available outside of ophthalmologists’ offices. DR screening was also frequently postponed during the pandemic, particularly in areas with high COVID-19 community transmission. For example, at the Wilmer Eye Institute, diabetic eye exams decreased from 1,145 visits in the 6 weeks prior to pandemic-related clinical practice changes to just 59 in the first 6 weeks after these changes were implemented.
Diabetic Retinopathy Market Segmentation
The diabetic retinopathy market in this report is studied on the basis of type, treatment type, and region. On the basis of type, the market is divided by proliferative diabetic retinopathy, and diabetic macular edema (DME). By treatment type, the market is classified into anti VEGF drug, steroid implants, laser surgeries, and vitrectomy. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Proliferative Diabetic Retinopathy segment held a dominant position in 2020.
On the basis of type, the proliferative diabetic retinopathy segment currently dominates the global diabetic retinopathy market and is expected to continue during the forecast period owing to increasing prevalence of the medical condition worldwide. Globally, in 2017, among adults aged 45 and over with diagnosed diabetes, 32.2% had cataracts, 8.6% had diabetic retinopathy, 7.1% had glaucoma, and 4.3% had macular degeneration. This can serve as a major opportunity for manufacturers to capitalize and expand their market share.
On the basis of treatment type, the treatment type, the laser surgeries segment dominated the global diabetic retinopathy market in 2020 and is anticipated to be dominant in the market. Since this treatment type has been available in the market for a long period, there is high acceptance and familiarity with the procedure. Thus, laser surgeries serve to be the lucrative investment pocket.
By Treatment Type
Neurosurgery Navigation Systems segment held a dominant position in 2020.
Region Segment Review
Region wise, North America dominated the market in 2020, owing to high prevalence of DR in this region, coupled with well-established infrastructure and increasing initiatives by the government to create awareness that would help people undergo screening for DR. However, Asia-Pacific is expected to witness considerable market growth during the forecast period due to rise in population base, high disposable incomes, and improvement in patient awareness about the treatment of diabetic retinopathy.
The major companies profiled in this report include Alimera Science, Inc., Abbvie, Inc., Ampio Pharmaceuticals, Inc., Bayer AG, Kowa Co., Ltd., Novartis, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., F-Hoffmann-La Roche Ltd, Valeant Pharmaceuticals International, Inc. (Bausch Health Companies Inc.).
Asia-Pacific region would exhibit the fastest CAGR of 14.4% during the forecast period.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the global diabetic retinopathy market along with the current trends and future estimations to explain the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the diabetic retinopathy market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing diabetic retinopathy market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of diabetic retinopathy used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the diabetic retinopathy market.
Diabetic Retinopathy Market Report Highlights
By Treatment Type
By List of key players profiled in the report:
According to the analyst’s perspective, globally, the use of therapeutics for the treatment of diabetic retinopathy is expected to increase in the near future, owing to high prevalence of diabetes coupled with rise in geriatric population. There are significant advancements in diabetic retinopathy treatment therapies for disease management. Asia-Pacific and LAMEA are expected to offer lucrative opportunities to market players due to the presence of ample growth opportunities in terms of unmet medical needs for the treatment of diabetic retinopathy.
Increase in the prevalence of diabetes, the geriatric population, the incidence of blindness due to diabetes, and the focus on awareness, which facilitates early diagnosis to control the diseases drive the market growth. However, this growth is restricted by dearth of skilled ophthalmologists and extended approval time for drugs. Conversely, emergence of combined therapies for treatment of diabetic macular edema and the emerging markets of Asia-Pacific and LAMEA are expected to provide several opportunities for market growth during the forecast period.